David Huang, MD
Ophthalmology · Corvallis, ORNPI 1053363747
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,000 of the $67,099 with a category attached, or 89.4%. Optovue, Inc. accounts for 82.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $55,083 and has fallen 87.9% since, to $6,646 in 2025. Among ophthalmology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $4193.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optovue, Inc.$55K
- Alcon Research LLC$12K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$217
- Oyster Point Pharma, Inc.$94
- Novartis$72
- Alcon$54
- plus $69 from 2 others
What the payments were for
- Consulting fees$6,51010%
- Speaking & faculty fees$60,00089%
- Food & beverage$5401%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optovue, Inc. | 1 | $55,000 |
| Alcon Research LLC | 3 | $11,592 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $217 |
| Oyster Point Pharma, Inc. | 1 | $94 |
| Novartis | 1 | $72 |
| Alcon | 1 | $54 |
| Amgen | 2 | $49 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solix System$55,000
- VYZULTA$119
How this compares
$67,099 in reported general payments places this provider in the 95th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 75 | $37,028 |
| RestasisCyclosporine | 20 | $23,620 |
| VyzultaLatanoprostene Bunod | 14 | $8,106 |
| Travoprost | 40 | $6,429 |
| Latanoprost | 417 | $5,031 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $4,690 |
| Timolol Maleate | 182 | $4,482 |
| Brimonidine Tartrate | 81 | $4,427 |
| Cyclosporine | 11 | $3,918 |
| Brinzolamide | 15 | $3,129 |
| Lotemax SmLoteprednol Etabonate | 11 | $2,752 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 124 | $2,448 |
| Prednisolone Acetate | 42 | $1,537 |
| Dorzolamide Hcl | 28 | $802 |
| Ofloxacin | 14 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta | $21 | $8,10614 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $217 | $2,75211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 ophthalmology providers in Oregon.
Other ophthalmology in Corvallis
- Gregory RichardCorvallis$3K
- Mark PennesiPortland$56K
- Rene ChoiPortland$21K
- Balamurali AmbatiEugene$19K
- Richard HoffmanEugene$17K
- Bart AdamsPendleton$17K
- Richard WeleberPortland$14K
- Aazim SiddiquiPortland$13K
- Kurt AndreasonBend$13K
- Poorav PatelMedford$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.